clinical trial · NCT04412668
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
aTyr Pharma, Inc.·phase2·completed·n = 36
SARS-CoV-2 (COVID-19) Severe PneumoniaEfzofitimod 1 mg/kgEfzofitimod 3 mg/kgPlacebo
brief summary
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
started
Jun 4, 2020
primary completion
Oct 23, 2020
completion
Oct 23, 2020
last updated
Aug 18, 2023
official title
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol